S-1/A: Propanc Biopharma Files Amended S-1 for Public Offering and Nasdaq Listing Amidst Significant Losses and Going Concern Doubts

Propanc Biopharma, a development-stage oncology company, is seeking to raise $4.6 million through a public offering of 1 million common shares at $5.00 per share and list on Nasdaq, despite reporting a $54.85 million net loss for the nine months ended March 31, 2025, and facing substantial doubt about its ability to continue as a going concern.

Summary

• Propanc Biopharma is a development-stage healthcare company focused on new cancer treatments, particularly for pancreatic, ovarian, and colorectal cancer, with its lead product candidate, PRP, currently in preclinical development.
• The company is undertaking a public offering of 1,000,000 shares of common stock at an assumed price of $5.00 per share, aiming to raise approximately $4.6 million in net proceeds for working capital and general corporate purposes.
• An application has been submitted to list the common stock on the Nasdaq Capital Market under the symbol PPCB; the offering is contingent upon this listing approval.
• The company reported a net loss of $54,851,839 for the nine months ended March 31, 2025, a significant increase from $1,461,950 for the same period in 2024, primarily due to increased stock-based compensation and consulting expenses.
• As of March 31, 2025, the accumulated deficit reached $121,550,059, and cash on hand was $50,760, raising substantial doubt about the company's ability to continue as a going concern.
• A 1-for-60,000 reverse stock split was effected on January 29, 2025, to facilitate the Nasdaq listing, proportionally adjusting outstanding stock options, warrants, and equity incentive plans.
• The company holds 85 granted, allowed, or accepted patents and 5 patent applications related to the use of proenzymes against solid tumors, covering its lead product candidate, PRP.
• Significant reliance on convertible debt financing continues, with several notes currently in default, posing risks of further dilution and negative price impact on common stock.
• Material weaknesses in internal control over financial reporting persist, including a lack of written documentation for policies, insufficient segregation of duties, and absence of an independent audit committee.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, including substantial doubt about its ability to continue as a going concern, significant accumulated losses, and reliance on dilutive debt. While the Nasdaq listing attempt and patent portfolio are positive, the overall financial health and early stage of product development present extremely high risks for investors.

Positives

• PRP has received Orphan Drug Designation status from the FDA for the treatment of pancreatic cancer in June 2017, which provides developmental incentives like protocol assistance, potential research grants, waiver of future application fees, and tax credits for U.S. clinical testing.
• The company has a substantial intellectual property portfolio with 85 granted, allowed, or accepted patents and 5 patent applications in key global jurisdictions related to proenzymes against solid tumors.
• Two scientific, peer-reviewed journal articles published by the company and its research partners have reached 10 citations and 4,500 reads, indicating scientific engagement and dissemination of research findings.
• A second Joint Research and Collaboration Agreement was established with the University of Jan and University of Granada in August 2022 to identify new intellectual property and investigate PRP's impact on the tumor microenvironment and its potential as a chemo-sensitizing agent.
• The company received a Certificate for Advance Overseas Finding from the Board of Innovation and Science Australia, entitling it to an up to 43.5% cash back benefit from overseas research and development expenses related to the planned Phase Ib clinical trial.

Negatives

• The company has no revenue-generating operations and has incurred significant operating losses since inception, with a net loss of $54,851,839 for the nine months ended March 31, 2025, compared to $1,461,950 for the same period in 2024.
• An accumulated deficit of $121,550,059 as of March 31, 2025, and negative cash flows from operations raise substantial doubt about the company's ability to continue as a going concern.
• The company is in default under certain loans payable, notes payable, and convertible notes payable, totaling approximately $552,000 subsequent to their maturity dates.
• Heavy reliance on substantial debt financing convertible into common stock, which cannot be repaid in cash, poses a significant risk of material adverse effect and negative price impact on the common stock due to conversion at a discount to market prices.
• The dual role of Chief Executive Officer and Chief Financial Officer held by James Nathanielsz may limit independent financial oversight, increase workload, and raise corporate governance concerns.
• Material weaknesses in internal control over financial reporting persist, including a lack of written documentation for policies, insufficient segregation of duties, and absence of an independent audit committee.
• Research and development expenses decreased due to cost-cutting measures stemming from a lack of working capital funding, potentially hindering product development progress.
• The company's common stock is currently quoted on the OTC Pink, a limited public market, and there is no assurance that the Nasdaq listing application will be approved or that a sustained trading market will develop.
• The company's stock may be deemed a 'penny stock' if it trades for less than $5.00 per share, which would limit liquidity and make it difficult for stockholders to sell shares.

Risks

• PRP remains in early stages of development and may never become commercially viable, leading to potential loss of investment.
• PRP may cause undesirable side effects that could negatively impact clinical trial results, limit its use, hinder further development, subject the company to product liability claims, and make commercialization difficult.
• Successful development of products is uncertain, which may materially harm results of operations.
• Clinical trials of PRP could be delayed or unsuccessful due to various factors, including regulatory hurdles, slow patient enrollment, non-compliance by third-party contractors, or unforeseen costs.
• Failure to obtain regulatory approval in jurisdictions outside the U.S. will prevent the company from marketing PRP in those regions.
• Inability to establish sales and marketing capabilities or secure third-party agreements could impede successful commercialization of product candidates.
• Substantial competition from major pharmaceutical and biotechnology companies, academic institutions, and research organizations may result in others developing or commercializing products more successfully.
• Even if PRP is commercialized, unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives could harm the business.
• Geopolitical conflicts, trade restrictions, and tariffs could adversely affect business, financial condition, and results of operations by increasing costs, disrupting supply chains, or limiting market access.
• The company's ability to continue as a going concern is in substantial doubt without obtaining adequate new debt or equity financings.
• Inability to remain in compliance with financial or other covenants in debt instruments could lead to default and creditors exercising rights over company assets.
• Significant losses are expected for the foreseeable future, and profitability may never be achieved or maintained.
• Reliance on substantial debt financing convertible into common stock, which cannot be repaid in cash, could lead to material adverse effects and negative price impact on common stock due to conversion at a discount.
• Raising additional capital will cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• The conversion of currently outstanding convertible notes will dilute the ownership interests of existing stockholders.
• The accounting method for convertible debt securities that may be settled in cash could have a material adverse effect on reported financial results.
• Maintaining cash in Australian financial institutions, which are uninsured beyond AUD $250,000, poses a risk of loss.
• Fluctuations in currency exchange rates may adversely impact cash flows and earnings.
• As a smaller reporting company, scaled disclosure requirements may make it challenging for investors to analyze results and financial prospects.
• A large number of shares of common stock may be sold in the market following this offering, which may significantly depress the market price.
• The market price of common stock may continue to be highly volatile, leading to potential loss of investment.
• The Chief Executive Officer also serving as Chief Financial Officer may create risks related to oversight, financial controls, and corporate governance.
• Difficulties in managing anticipated growth could disrupt operations.
• Material weaknesses in internal control over financial reporting, if not properly remediated, could result in material misstatements in consolidated financial statements.
• Failure to implement and maintain an effective system of internal control over financial reporting could lead to inaccurate financial reports or fraud.
• Significant increased costs will be incurred as a result of operating as a public company, including compliance with SEC and Nasdaq requirements.
• Judgments obtained against the company may not be enforceable due to substantial assets and key personnel being located outside the United States.
• Directors and officers have the right to indemnification, which may limit stockholders' ability to seek redress.
• The company is a controlled company under Nasdaq rules, allowing reliance on exemptions from certain corporate governance requirements that provide less protection to shareholders.
• The existence of Series B Super Voting Preferred Stock could delay, deter, or prevent a change in control or make management removal more difficult.

Future Outlook

The company expects to incur significant expenses and increasing operating losses for the foreseeable future as it progresses PRP into clinical trials, continues R&D, seeks regulatory approvals, establishes sales and marketing infrastructure, maintains intellectual property, and adds personnel. The ability to become profitable is dependent on successfully completing clinical trials, obtaining market approval, and commercializing PRP or other product candidates with significant market potential. The company will need substantial additional funding to achieve its business objectives, and there is no assurance that adequate financing will be available on acceptable terms or at all.

Management Comments

• "We are a development-stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer."
• "Utilizing our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body."
• "Our lead product candidate, PRP, is a variation upon our novel formulation and involves pro-enzymes, the inactive precursors of enzymes."
• "We believe that our existing cash and cash equivalents, along with the net proceeds from this offering, together with interest on cash balances, will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next twelve (12) to eighteen (18) months."
• "Management is currently seeking additional funds, primarily through the issuance of equity and/or debt securities for cash to operate our business."
• "We intend to develop our PRP to treat early-stage cancer and pre-cancerous diseases and as a preventative measure for patients at risk of developing cancer based on genetic screening."
• "Propanc intends to appoint Professor Kutz as Chief Medical Officer of Propanc in either a full-time or part-time executive officer capacity at a time that is mutually agreed upon between both parties."

Industry Context

Propanc Biopharma operates in the highly competitive biotechnology and pharmaceutical industries, characterized by continuous technological advancement. As a development-stage company, it faces competition from major pharmaceutical and biotechnology companies, academic institutions, and government agencies, many of which possess significantly greater financial resources and expertise. The company's focus on proenzyme-based cancer treatments positions it within the oncology sector, where numerous established therapies and products in clinical development exist. The industry trend towards cost containment and the need for reimbursement approval for new drugs will significantly impact the commercial viability of PRP, if approved, especially given the prevalence of generic alternatives and the higher prices associated with physician-administered drugs.

Comparison to Industry Standards

• Propanc Biopharma's status as a development-stage company with no revenue and recurring losses is common for early-stage biopharmaceutical firms, but its accumulated deficit of over $121 million and minimal cash balance of $50,760 as of March 31, 2025, indicate a more precarious financial position compared to many peers who typically maintain a longer cash runway or more robust funding rounds.
• The reliance on convertible debt with significant discounts and default interest rates, leading to substantial dilution, is a financing method often seen in distressed or highly speculative early-stage companies, which is generally less favorable than traditional equity financing rounds secured by more established biotechs.
• The 1-for-60,000 reverse stock split is an extreme measure, far more aggressive than typical reverse splits (e.g., 1:10 or 1:20) seen in the industry, highlighting severe stock price depreciation and the urgent need to meet Nasdaq's minimum bid price requirements.
• The persistence of material weaknesses in internal control over financial reporting, including lack of segregation of duties and an independent audit committee, falls below standard corporate governance practices expected even for smaller public companies in the biotech sector, which typically strive for stronger internal controls to build investor confidence.
• While the company's patent portfolio of 85 granted patents is a positive, the preclinical stage of its lead candidate PRP means it lags behind many competitors who have product candidates in later-stage clinical trials (Phase II or III), such as those developing novel immunotherapies or targeted therapies for similar cancer indications like pancreatic cancer (e.g., companies like Ipsen with Onivyde, or emerging biotechs with candidates in trials for pancreatic cancer like those targeting KRAS mutations or immune checkpoints).
• The dual role of CEO and CFO is unusual for a public company, even a smaller reporting company, and deviates from best practices in corporate governance that advocate for separation of these roles to ensure independent financial oversight and reduce key person risk, unlike more mature biopharma companies that typically have distinct executive leadership for these functions.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently involved in any litigation that it believes could have a material adverse effect on its financial condition or results of operations.
• The company is not aware of any pending or threatened legal proceeding against the company, its common stock, its subsidiary, or its officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.
• The SEC filed a complaint against Crown Bridge in August 2022 due to its violation of Section 15(a)(1) of the Securities Exchange Act of 1934, leading Crown Bridge to surrender all conversion rights in its held convertible notes, including the Crown Bridge Note held by the company.

Related Party Transactions

• As of March 31, 2025, the company owed its former director $0, after issuing 30,000 shares of common stock valued at $375,000 on January 23, 2025, in exchange for total outstanding loans of $74,395.
• The company leases its principal executive offices from North Horizon Pty Ltd., a related party owned and directed by Mr. Nathanielsz (CEO, CFO, Director) and his wife. The current three-year lease agreement, effective May 4, 2022, is for a monthly rent of $3,000 AUD.
• As of March 31, 2025, total rent payable to North Horizon Pty Ltd. was $124,976 USD, included in accrued expenses.
• Between November 2023 and May 2024, an institutional investor affiliated with director Josef Zelinger loaned the company an aggregate of $71,629 (AUD), which are non-interest bearing and payable on demand.
• In August 2024, the same affiliated institutional investor loaned the company an additional $85,000 AUD ($57,639 USD), non-interest bearing and payable on demand.
• Effective August 1, 2024, the company entered into a loan agreement with an institutional investor affiliated with Josef Zelinger for $150,000 AUD ($98,060 USD) at 12% interest, which is past due and in default.
• Between November and December 2024, an institutional investor affiliated with Josef Zelinger loaned the company an aggregate of $15,000 AUD ($9,731 USD), non-interest bearing and payable on demand.
• Effective December 3, 2024, the company entered into a loan agreement with an institutional investor affiliated with Josef Zelinger for $175,000 AUD ($113,485 USD) at 12% interest.
• In January 2025, an institutional investor affiliated with Josef Zelinger loaned the company an aggregate of $25,000 AUD ($15,485 USD), non-interest bearing and payable on demand.
• On July 5, 2023, the company entered into a letter agreement with an institutional investor affiliated with Josef Zelinger for a $230,000 AUD ($153,256 USD) loan with a three-year term at 10% interest, and issued 250 warrants to purchase common stock to this investor.
• On April 12, 2025, the company entered into a loan agreement with an institutional investor affiliated with Josef Zelinger for $63,188 AUD ($39,733 USD) at 12% interest.
• James Nathanielsz (CEO, CFO, Director) and his wife, Sylvia Nathanielsz (part-time employee), have employment agreements with the company, including salary, pension contributions, and vehicle allowances. Mr. Nathanielsz's annual base salary was increased to $600,000 AUD effective July 1, 2022.
• Dr. Julian Kenyon (Chief Scientific Officer and Director) has a services agreement with an annual salary of $54,000 AUD.
• Josef Zelinger (Director) has a director agreement with a monthly salary of $250 AUD.
• All intercompany loans made by the parent company to its subsidiary, Propanc PTY LTD, have not been repaid as of March 31, 2025, and are not expected to be repaid in the foreseeable future.

Stakeholder Impact

• **Shareholders:** Existing shareholders will experience significant dilution from the public offering and potential future conversions of outstanding convertible debt. The 1:60,000 reverse stock split has already drastically reduced the number of shares, and the ongoing financial losses and 'going concern' doubt pose a high risk of losing their entire investment. The control held by the CEO through Series B Preferred Stock limits the influence of common shareholders.
• **Employees:** The company's financial instability and cost-cutting measures, including reduced R&D expenses, could impact job security and future compensation. Stock-based compensation has been a significant component of remuneration, but its value is highly dependent on the volatile stock price.
• **Customers (Future):** If PRP is successfully developed and commercialized, it could offer a new treatment option for patients with pancreatic, ovarian, and colorectal cancer. However, the long development timeline and uncertain regulatory approval process mean this impact is distant and speculative.
• **Suppliers/Creditors:** The company's default on several loans and notes indicates a high risk for creditors. The ability to repay obligations is dependent on future capital raises, which are uncertain. Vendors who accepted shares for payment of accounts payable are now exposed to the company's stock price volatility.
• **Regulatory Bodies:** The company's efforts to comply with SEC reporting requirements and Nasdaq listing rules are ongoing. The identified material weaknesses in internal controls could lead to further scrutiny or penalties if not remediated.

Next Steps

• Complete the public offering of 1,000,000 shares of common stock.
• Obtain approval for listing common stock on the Nasdaq Capital Market under the symbol PPCB.
• Initiate a Phase Ib First-In-Human (FIH) study in patients with advanced solid tumors to evaluate the safety, pharmacokinetics, and anti-tumor efficacy of PRP.
• Continue research and development activities, including the POP1 joint research and drug discovery program to produce a backup clinical compound to PRP.
• Negotiate and secure further research and development collaborations with the University of Jan and other contract research organizations.
• Address material weaknesses in internal control over financial reporting by establishing an audit committee, adding experienced accounting and financial personnel, and retaining third-party consultants.
• Negotiate with lenders to amend maturity dates for outstanding defaulted convertible notes and loans.
• Potentially explore additional financing agreements, including equity or debt, to fund ongoing operations and R&D efforts.

Key Dates

Recommendation

Propanc Biopharma presents an extremely high-risk investment profile. The company is a development-stage biopharma with no revenue and a history of significant and escalating losses, culminating in a $54.85 million net loss for the nine months ended March 31, 2025. Its cash position is critically low at $50,760, leading to a 'going concern' qualification from its auditors, indicating substantial doubt about its ability to continue operations. The recent 1-for-60,000 reverse stock split, while intended to facilitate a Nasdaq listing, is a drastic measure reflecting severe prior stock price depreciation and will result in massive dilution for existing shareholders. The company's heavy reliance on convertible debt, much of which is in default and convertible at significant discounts to market prices, poses an ongoing threat of further dilution and downward pressure on the stock. While the lead product candidate, PRP, has Orphan Drug Designation and a patent portfolio, it remains in preclinical development, implying a very long and uncertain path to commercialization. Compounding these issues are identified material weaknesses in internal financial controls and the dual role of CEO/CFO, which raise governance concerns. Given the dire financial state, high operational risks, and the speculative nature of its core business, the stock is highly likely to experience continued downward pressure and is not suitable for investment.

Keywords

Biopharma, Cancer Treatment, Oncology, PRP, Preclinical Development, SEC Filing, S-1/A, Public Offering, Nasdaq Listing, Reverse Stock Split, Convertible Debt, Going Concern, Intellectual Property, Clinical Trials, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer, Proenzymes